Clinical trials: Atezolizumab
Triple-Negative Breast Cancer
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
- Trial name
- NCT04177108
- Testing
- Atezolizumab, Ipatasertib, Paclitaxel
- Where
- 182 sites in United States, Argentina and 35 more
- Volunteers
- 242 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC…
- Trial name
- NCT04426825
- Testing
- Atezolizumab, Bevacizumab
- Where
- 10 sites in China
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Glioblastoma Multiforme
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis.
- Trial name
- NCT05423210
- Testing
- Atezolizumab + FSRT radiation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stony Brook University
Urothelial Carcinoma
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.
- Trial name
- NCT03272217
- Testing
- Atezolizumab, Bevacizumab
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arjun Balar, MD
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the…
- Trial name
- NCT07407933
- Testing
- YL201, Atezolizumab
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 118 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat) administered via intravenous infusion or via subcutaneous…
- Trial name
- NCT04471415
- Testing
- DRP-104, atezolizumab
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 61 people
- Sponsor
- Dracen Pharmaceuticals, Inc.
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Rectal Cancer
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
- Trial name
- TARZAN (NCT04017455)
- Testing
- Atezolizumab, Bevacizumab
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- The Netherlands Cancer Institute
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
This phase II trial studies how well bevacizumab and atezolizumab with or without cobimetinib work in treating patients with untreated melanoma that has spread to the brain (brain metastases).
- Conditions
- BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT03175432
- Testing
- Atezolizumab, Bevacizumab, Cobimetinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
This study is for patients with metastatic colorectal cancer who are candidates for resection of metastases. This study will be conducted sequentially with 2 cohorts: 1.) Monotherapy Cohort and 2.) Combination Cohort…
- Trial name
- ATELIER (NCT03340558)
- Testing
- Atezolizumab, Cobimetinib
- Where
- United States
- Sponsor
- Niharika Mettu
Venous Thrombosis
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
The treatment strategies for HCC with PVTT is still controversial, and differ substantially between the west and the east. According to western guidelines, including those of the EASL, BCLC, and AASLD, PVTT is regarded as a…
- Trial name
- TALENTOP (NCT04649489)
- Testing
- Atezolizumab & Bevacizumab, Surgery followed by atezolizumab and bevacizumab
- Where
- 23 sites in China
- Volunteers
- 501 people
- Sponsor
- Jia Fan
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Large Cell Neuroendocrine Carcinoma of the Lung
Atezolizumab in Large Cell Neuroendocrine Carcinoma
Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a rare and aggressive malignancy with limited prospective evidence to guide systemic treatment.
- Trial name
- LANCE (NCT06049966)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 3 sites in Greece
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Oncology Center of Biochemical Education And Research
Cancer
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
This study is looking at outcomes in people with advanced cancers who have exhausted standard treatment options and are accessing off indication or unregistered drugs or combinations of drugs through compassionate access from the…
- Trial name
- TAILOR (NCT04801966)
- Testing
- Trametinib, Cobimetinib, Binimetinib
- Where
- Australia
- Volunteers
- 3 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT04631029
- Testing
- Atezolizumab, Carboplatin, Entinostat
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)